Literature DB >> 9159347

Analysis of Ki-ras, p53, and MDM2 genes in uterine leiomyomas and leiomyosarcomas.

K L Hall1, M G Teneriello, R R Taylor, S Lemon, M Ebina, R I Linnoila, J H Norris, R C Park, M J Birrer.   

Abstract

Uterine sarcomas are unusual neoplasms of the female genital tract whose molecular etiology is largely unknown. We examined 20 leiomyomas as well as 23 uterine leiomyosarcomas for the presence of mutations in the Ki-ras and p53 genes, and overexpression of the MDM2 gene. Codons 12, 13, and 61 from the Ki-ras gene were characterized for the presence of mutations by restriction enzyme polymorphisms using mismatched primers and nucleic acid sequencing as appropriate. Activated Ki-ras genes were identified in 3/20 leiomyomas and 0/23 leiomyosarcomas. The p53 gene was analyzed by SSCP, nucleic acid sequencing, and immunohistochemical staining. None of 20 leiomyomas and 6/23 leiomyosarcomas exhibited p53 abnormalities. The SSCP/sequencing results did not consistently correlate with the IHC staining. MDM2 overexpression occurred in 0/20 leiomyomas and 3/23 sarcomas. Clinical correlation suggested that tumors with p53 mutations have a higher histologic grade or stage at presentation. We conclude that leiomyomas and leiomyosarcomas have different patterns of molecular alterations and are separate biologic entities. In addition, p53 and MDM2 overexpression may play a role in the development of a subset of leiomyosarcomas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9159347     DOI: 10.1006/gyno.1997.4653

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

1.  Uterine smooth muscle tumor analysis by comparative genomic hybridization: a useful diagnostic tool in challenging lesions.

Authors:  Sabrina Croce; Agnes Ribeiro; Celine Brulard; Jean-Christophe Noel; Frederic Amant; Eberhard Stoeckle; Mojgan Devouassoux-Shisheborah; Anne Floquet; Laurent Arnould; Frederic Guyon; Florence Mishellany; Delphine Garbay; Tine Cuppens; Michal Zikan; Agnès Leroux; Eric Frouin; Pierre Duvillard; Philippe Terrier; Isabelle Farre; Isabelle Valo; Gaetan M MacGrogan; Frederic Chibon
Journal:  Mod Pathol       Date:  2015-05-01       Impact factor: 7.842

2.  The MDM2 promoter polymorphism SNP309T-->G and the risk of uterine leiomyosarcoma, colorectal cancer, and squamous cell carcinoma of the head and neck.

Authors:  P Alhopuro; S K Ylisaukko-Oja; W J Koskinen; P Bono; J Arola; H J Järvinen; J-P Mecklin; T Atula; R Kontio; A A Mäkitie; S Suominen; I Leivo; P Vahteristo; L-M Aaltonen; L A Aaltonen
Journal:  J Med Genet       Date:  2005-09       Impact factor: 6.318

3.  Immunohistochemical detection of promyelocytic leukemia zinc finger and histone 1.5 in uterine leiomyosarcoma and leiomyoma.

Authors:  Mazdak Momeni; Tamara Kalir; Sara Farag; Yayoi Kinoshita; Taisha Y Roman; Linus Chuang; David A Fishman; David E Burstein
Journal:  Reprod Sci       Date:  2014-04-30       Impact factor: 3.060

4.  DNA copy number changes in development and progression in leiomyosarcomas of soft tissues.

Authors:  W El-Rifai; M Sarlomo-Rikala; S Knuutila; M Miettinen
Journal:  Am J Pathol       Date:  1998-09       Impact factor: 4.307

5.  Human pancreatic leiomyosarcoma (PZX-7) growing as a serially transplantable xenograft in immunosuppressed mice.

Authors:  A Zalatnai; J Bocsi; T Csákány; T Fekete; J Lásztity
Journal:  Int J Pancreatol       Date:  1999-08

6.  Transition from squamous cell carcinoma to adenocarcinoma in adenosquamous carcinoma of the lung.

Authors:  H Kanazawa; M Ebina; N Ino-Oka; M Shimizukawa; T Takahashi; S Fujimura; T Imai; T Nukiwa
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

7.  Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors.

Authors:  Rainer Lehtonen; Maija Kiuru; Sakari Vanharanta; Jari Sjöberg; Leena-Maija Aaltonen; Kristiina Aittomäki; Johanna Arola; Ralf Butzow; Charis Eng; Kirsti Husgafvel-Pursiainen; Jorma Isola; Heikki Järvinen; Pasi Koivisto; Jukka-Pekka Mecklin; Päivi Peltomäki; Reijo Salovaara; Veli-Matti Wasenius; Auli Karhu; Virpi Launonen; Nina N Nupponen; Lauri A Aaltonen
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

8.  Targeting the p53 Pathway in Ewing Sarcoma.

Authors:  Paul M Neilsen; Kathleen I Pishas; David F Callen; David M Thomas
Journal:  Sarcoma       Date:  2010-12-09

9.  Association of XRCC1 Arg399GIn and Tp53 Arg72Pro polymorphisms and increased risk of uterine leiomyoma - A case-control study.

Authors:  Minoo Yaghmaei; Saeedeh Salimi; Lida Namazi; Farzaneh Farajian-Mashhadi
Journal:  Genet Mol Biol       Date:  2015-11-24       Impact factor: 1.771

Review 10.  Potential Therapeutic Targets in Uterine Sarcomas.

Authors:  Tine Cuppens; Sandra Tuyaerts; Frédéric Amant
Journal:  Sarcoma       Date:  2015-10-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.